Active, not recruitingPhase 3NCT04961567
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biogen
- Principal Investigator
- Medical DirectorBiogen
- Intervention
- Litifilimab(drug)
- Enrollment
- 562 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Arizona Arthritis & Rheumatology Associates, P.C., Glendale, Arizona, United States
- Care Access Research - Huntington BeachCare Access Research - Huntington Beach, Huntington Beach, California, United States
- Valerius Medical Group, Los Alamitos, California, United States
- The Practice of Medicine, Los Angeles, California, United States
- R. Srinivasan, M.D., Inc. dba Monterey Park Medical Center, Monterey Park, California, United States
- Neurovations, Napa, California, United States
- Joo-Hyung Lee MD, Orange, California, United States
- Medvin Clinical Research, Whittier, California, United States
- RASF - Clinical Research Center, Boca Raton, Florida, United States
- University of Florida, Gainesville, Florida, United States
- Vida Clinical Research, Kissimmee, Florida, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- HMD Research, LLC, Orlando, Florida, United States
- Clinical Research of West Florida, Inc., Tampa, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04961567 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology